February 6, 2020 / 6:45 AM / 13 days ago

Sanofi eyes more growth this year as it narrows focus

PARIS, Feb 6 (Reuters) - Sanofi on Thursday said it was expecting earnings per share to grow around 5 percent at constant exchange rates in 2020, weeks after pledging to focus on vaccines and key treatments like its eczema medicine Dupixent until 2022.

The French drugmaker said net income was up 18.4% to 1.68 billion euros ($1.85 billion) in the fourth quarter of last year on the back of double digit growth sales at its speciality care business Genzyme and its vaccines unit. ($1 = 0.9094 euros) (Reporting by Matthias Blamont; Editing by Sudip Kar-Gupta)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below